Treatment of Pseudomonas aeruginosa Infections
Antimicrobial Activity and Guidelines
- The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines do not recommend tigecycline for Pseudomonas infections due to its inadequate activity 1
Clinical Implications and Alternative Treatments
- For carbapenem-resistant Pseudomonas aeruginosa (CRPA) infections, ESCMID guidelines suggest therapy with ceftolozane-tazobactam if active in vitro, rather than tigecycline 1
- For non-severe CRPA infections, old antibiotics should be chosen from among in vitro active agents according to the source of infection 1
- The FDA has issued a Boxed Warning for tigecycline, recommending consultation with infectious disease specialists when considering its use 2
Recommended Alternative Treatment Options
- For carbapenem-resistant Pseudomonas aeruginosa (CRPA), ESCMID guidelines recommend ceftolozane-tazobactam if active in vitro for severe infections 1
- For non-severe infections, use of old antibiotics that show in vitro activity is recommended by ESCMID guidelines 1
- Antipseudomonal drugs that may be effective include carbapenems, cephalosporins (ceftazidime, cefepime), fluoroquinolones, aminoglycosides, and polymyxins, depending on susceptibility patterns 1